Business Development 2000-2009

Total revenues²

6,910

7,721

7,521

7,364

6,017

5,887

4,485

7,081

7,590

7,747

2.1

Pharmaceuticals

3,047

3,484

3,265

3,458

3,601

3,905

2,338

4,900

5,456

5,812

6.5

Merck Serono

1,941

2,228

1,850

1,546

1,619

1,817

1,938

4,480

5,014

5,345

6.6

Generics³

790

936

1,096

1,585

1,625

1,712

–

–

–

–

–

Consumer Health Care

299

320

319

327

357

376

400

420

442

467

5.7

Imaging³

17

–

–

–

–

–

–

–

–

–

–

Chemicals

1,679

1,729

1,791

1,707

1,696

1,906

2,113

2,152

2,127

1,935

–9.0

Liquid Crystals

313

297

383

443

589

741

895

916

878

733

–17

Performance & Life Science Chemicals

1,174

1,216

1,216

1,083

1,107

1,165

1,218

1,236

1,249

1,202

–3.8

Electronic Chemicals³

192

216

192

181

–

–

–

–

–

–

–

Laboratory Distribution³

2,374

2,754

2,711

2,427

582

–

–

–

–

–

–

Intragroup sales, Laboratory

–190

–246

–246

–228

–62

–

–

–

–

–

–

Corporate and Other

–

–

–

–

200

76

34

29

7

–

–

Generics³

–

–

–

–

–

–

1,825

1,398

–

–

–

Operating result

746

877

616

736

776

883

799

976

1,131

649

–43

Pharmaceuticals

455

581

272

389

391

454

217

417

655

403

–39

Chemicals

247

204

260

316

420

492

641

631

558

324

–42

Laboratory Distribution³

44

92

84

79

21

–

–

–

–

–

–

Corporate and Other

0

0

0

–48

–56

–63

–60

–72

–81

–78

–3.5

Generics³

–

–

–

–

–

–

307

189

–

–

–

Earnings before interest and tax (EBIT)

747

1,286

559

538

1,044

956

1,031

200

731

621

–15

EBIT before depreciation and amortization (EBITDA)

1,184

1,694

985

1,008

1,419

1,245

1,334

1,858

1,947

1,625

–17

Profit before tax

524

1,078

412

423

961

893

982

–111

575

486

–15

Profit after tax

262

655

215

218

672

673

1,001⁴

3,520⁴

379

377

–0.6

Free cash flow

324

664

441

442

1,889

657

–1,073⁴

–1,473⁴

438

812

85

Capital expenditure on property, plant and equipment

427

470

377

281

234

268

253⁴

283⁴

395

467

18

Research and development

546

577

608

605

599

713

615

1,028

1,234

1,345

8.9

Total assets

8,235

8,255

7,511

6,982

5,754

7,281

8,102

14,922

15,645

16,713

6.8

Net equity

1,947

2,336

2,054

2,363

2,800

3,329

3,807

8,688

9,563

9,514

–0.5

Employees (number as of December 31)

33,520

34,294

34,504

34,206

28,877

29,133

25,531

30,968

32,800

33,062

0.8

Return on sales in % (ROS: operating result/total revenues)

10.8

11.4

8.2

10.0

12.9

15.0

17.8

13.8

14.9

8.4

Earnings per share in €

1.44

3.66

1.18

1.15

3.47

3.40

5.07⁴

16.21⁴

1.69

1.68

–0.6

Dividend per share in €

0.90

0.95

1.00

0.80

0.80

0.85

0.90

1.20

1.50

1.00

–33

One-time bonus per share in €

–

–

–

–

0.20

–

0.15

2.00

–

–